5-Hydroxytryptophan (5-HTP)
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Chemical Class | Non-proteinogenic amino acid (serotonin precursor) |
| Molecular Formula / CAS | C₁₁H₁₂N₂O₃ · CAS 56-69-9 |
| Primary Botanical Source(s) | Griffonia seed (Griffonia simplicifolia) |
| Plant Part | Seed |
| Typical Content | Griffonia seed is the only significant commercial botanical source of concentrated 5-HTP, typically extracted and standardised to 90%+ purity |
| Solubility / Format | Water-soluble amino acid; available as high-purity extract powder |
| Sourcing Status | Product-live — genuine match via Herbuno’s Griffonia seed extract |
| Buy from Herbuno | 5-HTP 98% Extract Powder (Griffonia Simplicifolia) |
Name origin: 5-Hydroxytryptophan (5-HTP) is named systematically for its chemical structure, a hydroxylated form of the amino acid tryptophan. Traditional use: Griffonia simplicifolia, a woody shrub native to West and Central Africa, has a traditional medicinal use in its native region, though 5-HTP itself was never used as an isolated traditional preparation; commercial extraction of 5-HTP from Griffonia seed developed specifically because the plant carries an unusually high, concentrated natural content of the compound compared to virtually any other food or botanical source. Research trajectory: 5-HTP research began with its role as the direct metabolic intermediate between dietary tryptophan and serotonin, and clinical interest developed substantially through the 1970s–90s around depression, given serotonin’s role in mood regulation; research has since expanded into sleep, anxiety, migraine, fibromyalgia and appetite/satiety, making 5-HTP one of the more clinically-studied compounds in the HerbIQ index by total published trial count. Commercial source: Griffonia seed is the standard and essentially sole practical commercial source of concentrated 5-HTP, and Herbuno’s standardised extract reflects this well-established, genuine botanical match.
Evidence for 5-Hydroxytryptophan (5-HTP) Applications
5-HTP is the direct metabolic intermediate between dietary tryptophan and serotonin, produced by the rate-limiting enzyme tryptophan hydroxylase and then rapidly converted to serotonin by aromatic L-amino-acid decarboxylase. Because 5-HTP, unlike serotonin itself, readily crosses the blood-brain barrier, oral 5-HTP supplementation bypasses the normal rate-limiting step in serotonin synthesis, which is the pharmacological basis for its use across mood, sleep and appetite research; a comprehensive review covering natural occurrence, physiology and toxicology found the majority of clinical trials concern depression, anxiety, panic attacks and sleep disorders (Turone et al. 2020). Claim strength: Moderate.
A 12-week, single-blinded, randomised controlled trial in older adults tested 100 mg/day 5-HTP against no supplementation, finding an overall favourable effect on certain sleep quality components (measured by both subjective questionnaire and objective actigraphy), an increase in serum serotonin concentration, and improved gut microbiota composition, with benefits most pronounced in participants classified as poor sleepers at baseline (et al. 2024). This is one of the more recent and methodologically detailed human trials specific to 5-HTP. Claim strength: Moderate.
For depression specifically, a review of adjunctive 5-HTP therapy summarises several controlled trials in depressed inpatients, including studies where 5-HTP (200–300 mg/day) combined with a tricyclic antidepressant outperformed the antidepressant alone, with nausea reported as the most common adverse event and hypomania observed in a subset of patients, reversible upon dose reduction (Jangid et al.). The review also notes that no FDA-approved drug currently contains 5-HTP as an active pharmaceutical ingredient, despite this multi-decade research history. Claim strength: Moderate.
Because 5-HTP directly increases serotonin synthesis, it carries a genuine and well-documented safety consideration: combining 5-HTP with serotonergic medications (including SSRIs, SNRIs, MAOIs, and certain migraine or pain medications) raises the risk of serotonin syndrome, a potentially serious condition caused by excess serotonergic activity. This is not a generic herbal caution but a specific, mechanism-driven interaction risk that should be reflected in product labelling and safety documentation. Claim strength: High (safety).
5-HTP research has also extended into satiety and appetite regulation, migraine prophylaxis, and fibromyalgia pain management, reflecting serotonin’s broad physiological role beyond mood alone. Human absorption of oral 5-HTP is rapid (peak plasma levels around 1.5 hours) with a short elimination half-life of approximately 2 hours, information relevant to dosing frequency in formulated products. Claim strength: Moderate.
Dosage & Formulator Specification
Human clinical trials have used 5-HTP doses ranging from 100 mg/day (sleep quality research) up to 200–300 mg/day (depression research, generally as an adjunct to other treatment), with absorption occurring rapidly (peak plasma concentration around 1.5 hours after oral dosing) and a relatively short elimination half-life of roughly 2 hours.
Analytical quantification of 5-HTP is performed by HPLC, and because Griffonia seed extract can be sold at varying purity grades, formulators should confirm the specific 5-HTP percentage rather than assuming a standard concentration; Herbuno’s extract is standardised to 98% purity.
The single most important formulation and labelling consideration for 5-HTP is its serotonin syndrome interaction risk with serotonergic medications (SSRIs, SNRIs, MAOIs, tramadol, triptans and related drugs); finished products should carry clear guidance advising against combination with these medication classes without medical supervision.
Regulatory positioning for 5-HTP follows established dietary supplement pathways in the United States and most markets, where it is sold as a food supplement rather than an approved pharmaceutical drug; no FDA-approved drug currently contains 5-HTP as its active ingredient despite its multi-decade clinical research history. Formulators should verify current regulatory status in each specific target market.
Frequently Asked Questions — 5-Hydroxytryptophan (5-HTP)
5-HTP is one metabolic step closer to serotonin than dietary tryptophan. The body converts tryptophan to 5-HTP via the rate-limiting enzyme tryptophan hydroxylase, then converts 5-HTP to serotonin; taking 5-HTP directly bypasses this first, rate-limiting conversion step.
This requires medical guidance and is a genuine safety concern, not a minor caution. Combining 5-HTP with serotonergic medications such as SSRIs, SNRIs, or MAOIs raises the risk of serotonin syndrome, a potentially serious condition caused by excess serotonergic activity.
A 12-week randomised controlled trial in older adults found that 100 mg/day of 5-HTP had an overall favourable effect on certain sleep quality measures and increased serum serotonin levels, with the benefit most noticeable in participants who were poor sleepers at the start of the study.
No. Despite decades of clinical research, including trials showing benefit as an add-on to tricyclic antidepressants, no FDA-approved drug currently contains 5-HTP as its active ingredient. It is sold as a dietary supplement rather than a regulated pharmaceutical in most markets.
Related compounds: Hypericin, L-DOPA